Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (15418)	6/23/2001 2:10:50 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

Amevive works, the longer the better and Xanelim works fairly well earlier, and stops working very early too. TSC,"anger market, and the rest of the conspiracies are irrelevant. Amevive is the best, and it will be first at the FDA and in the market. xoma is close to all time high and Monday comes my view is that it will nicely cool off (already did, I watch Level II and the offers above $14.80 were choking each other and suddenly price strength break down), xoma is overvalue. It seems you are right and the details were out earlier, (most of the presentation at the Dermatology Congress had most of the information anyway). Monday comes another selloff on Biogen? Wellcome, I will keep buying a cheap stock (same as I have done and will with DNA). Funds behavior? they are not going to accumulate xoma at premiun prices in a bear market, so expect it to go DOWN on Monday.